What to Know About Syfovre and Izervay for Geographic Atrophy
Feb 18, 2024 · Two new drugs – Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) – were approved in 2023 for geographic atrophy, a potentially debilitating type of dry age-related macular degeneration (AMD).
FDA Approves First Geographic Atrophy Treatment SYFOVRE - Macular
Feb 18, 2023 · A groundbreaking, new frontier in macular degeneration treatment has been announced! With the FDA’s approval of Syfovre™, for the first time there’s hope to preserve sight for millions of patients with the advanced stage of dry macular degeneration (dry AMD), called geographic atrophy (GA).
Macular Degeneration Breakthroughs: Emerging Treatments, New …
May 27, 2024 · New treatments for macular degeneration may help preserve your eyesight for longer, without the need for frequent injections. Some of these treatments include retinal gene therapy and the "port" delivery system.
First drug to treat dry AMD approved for use in the US
Feb 21, 2023 · The first ever drug to treat dry age-related macular degeneration (AMD) has been approved for use in the US. The Food and Drug Administration (FDA) has cleared the drug pegcetacoplan, known as Syfovre, for use in patients.
New Treatments for Age-Related Macular Degeneration
May 23, 2024 · Two new drugs that target the complement cascade and stop it from attacking the retina have recently been approved by the FDA: Pegcetacoplan (SYFOVRE) and avacincaptad pegol (Izervay). Like currently available treatments for wet AMD, these drugs are injected directly into the patient’s eye.
New Treatments for Macular Degeneration on the Horizon
May 31, 2023 · Axitinib – A new type of anti-VEGF drug — axitinib injectable suspension, CLS-AX (Clearside) — that is administered not into the center of the eye but into a space between the outer layers of the eyeball, has demonstrated the ability for patients to go 6 months and beyond between treatments in early clinical trials.
New drug for dry AMD - your questions answered - Macular …
Apr 4, 2023 · In February we shared the exciting news that the first-ever drug to treat dry age-related macular degeneration (AMD) has been approved in the US. Pegcetacoplan, known as Syfovre, was cleared for use in patients by the Food and Drug Administration (FDA).
FDA Approves Izervay: New Drug Slows Progression of …
Aug 16, 2023 · The FDA has approved Izervay, a new drug that slows the progression of geographic atrophy, an advanced stage of age-related macular degeneration (AMD).
Ocugen Clinical Trial Could Lead to Breakthrough One-Time ... - Macular
NORTHAMPTON, Ma., Dec. 19, 2023 — The American Macular Degeneration Foundation received news that the first patient has been dosed in a safety and efficacy clinical trial of a one-time gene therapy treatment for advanced dry macular degeneration (dry AMD), also known as Geographic Atrophy (GA).
New FDA-approved drug can slow vision loss for those with ... - CBS News
Mar 1, 2023 · The Food and Drug Administration recently approved the first drug to treat geographic atrophy, a form of macular degeneration, which affects a person's central vision.